Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic. Read a statement...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video

The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
RDMD and MSU Collaborating for IBM Research

We are excited to announce a new collaboration with RDMD, a company that aims to jumpstart research for patients...
New Insights on sporadic Inclusion body myositis (sIBM) pathogenesis

Dr. Conrad "Chris" Weihl joins MSU live for a session titled "New Insights on sporadic Inclusion body myositis (sIBM)...
The NT5C1A Antibody Test and its Role in the Diagnosis of Inclusion Body Myositis

Learn more about the NT5CIA antibody and its association with inclusion body myositis from Dr. Kevin Dooley, a retired...